Table 3.
Univariate and multivariate analyses of prognostic factors for OS
| Variables | Univariate analysis
|
Multivariate analysis
|
||
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR (95% CI) | |
| Age (<47/≥47 years) | 0.211 | 1.119 (0.881–1.652) | ||
| Sex (male/female) | 0.089 | 1.496 (0.916–1.658) | 0.136 | 1.463 (0.885–1.532) |
| KPS (≥90/<90) | 0.385 | 0.723 (0.348–1.503) | ||
| BMI (<19.7/≥19.7 kg/m2) | 0.803 | 1.034 (0.796–1.342) | ||
| Number of involved sites (>1/1) | 0.039 | 1.685 (1.049–2.766) | 0.335 | 1.379 (0.758–1.763) |
| Synchronous metastasis (present/absent) | 0.083 | 1.377 (0.796–1.942) | 0.149 | 1.129 (0.843–1.362) |
| Lung metastasis (present/absent) | 0.254 | 1.225 (0.842–1.698) | ||
| Bone metastasis (present/absent) | 0.342 | 0.723 (0.348–1.503) | ||
| Liver metastasis (present/absent) | 0.195 | 1.373 (0.863–1.782) | ||
| Distant nodal metastasis (present/absent) | 0.259 | 0.785 (0.652–1.623) | ||
| Chemotherapy regimen (TP/PF/others) | 0.136 | 1.273 (0.865–1.847) | ||
| Complete response (yes/no) | 0.011 | 0.623 (0.433–0.897) | 0.013 | 0.681 (0.574–0.902) |
| WBC, ×109 counts/L (<5.3/≥5.3) | 0.142 | 1.373 (0.824–1.685) | ||
| Hemoglobin, g/L (<127/≥127) | 0.231 | 1.182 (0.736–1.596) | ||
| Platelet, ×109 counts/L (<215/≥215) | 0.756 | 1.068 (0.876–1.258) | ||
| Serum LDH, U/L (<241/≥241) | 0.876 | 0.978 (0.771–1.196) | ||
| PNI (<51/≥51) | 0.002 | 1.845 (1.246–2.731) | 0.005 | 1.732 (1.216–2.892) |
| EA/IgA titers (≥1:20/<1:20) | 0.268 | 1.045 (0.781–1.358) | ||
| VCA/IgA titers (≥1:160/<1:160) | 0.036 | 1.358 (1.069–1.964) | 0.187 | 1.119 (0.864–1.485) |
Abbreviations: OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; KPS, Karnofsky performance score; BMI, body mass index; WBC, white blood cell; LDH, lactate dehydrogenase; TP, paclitaxel + cisplatin; PF, cisplatin + 5-fluorouracil; PNI, prognostic nutritional index; EA, early antigen; VCA, viral capsid antigen; IgA, immunoglobulin A.